Lexeo Therapeutics LXEO Cash Flow Statement (2022-2026)

NASDAQ LXEO
$2.94 -0.06 (-2.00%)
As of: Oct 22, 2026 · 1:11 PM EDT
Reported Financials

Lexeo Therapeutics Quarterly Cash Flow Statement

Periods 16 quarters
Latest Jun 2026

Lexeo Therapeutics reported cash from operations of -$17.60M and free cash flow of -$17.60M for the quarter ended Jun 2026, up 35.4% year over year. This cash flow statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -17.06M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M-25.87M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges 0.05M0.09M0.07M0.08M0.08M0.08M0.09M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M
Depreciation & Amortization (CF)Dep. & Amort. 0.06M0.06M0.06M0.08M0.08M0.07M0.08M0.08M0.08M0.06M0.06M0.07M0.07M0.07M0.07M
Share-based CompensationStock Comp. 0.43M0.52M0.40M0.97M0.87M0.80M2.33M2.85M3.79M3.51M3.70M3.07M2.65M2.71M2.76M5.69M
Other non-cash itemsOther Non-Cash 0.30M0.32M0.31M0.30M0.33M0.32M0.34M0.35M0.37M0.36M0.37M0.38M0.39M0.39M0.40M
Change in Working Capital
Change in Account PayablesChange Payables -1.22M1.04M-1.91M0.29M0.39M0.64M1.06M2.72M-2.04M5.14M8.36M-15.27M0.20M-1.60M0.83M
Change in Accured ExpensesChange Accured Exp. -0.91M-1.79M1.20M4.80M-2.12M3.89M-3.87M5.27M-1.92M2.32M-7.14M1.00M-0.62M-1.09M0.69M
Change in Other Operating AssetsOther Assets Change 0.83M-0.52M0.19M0.04M-0.70M0.20M-0.86M0.27M2.08M0.36M2.20M-2.14M1.58M1.12M-0.90M
Change in Other Operating LiabilitiesOther Liabilities Change -0.19M-0.33M-0.28M-0.49M-0.32M-0.32M-0.32M-0.34M-0.36M-0.36M-0.36M-0.38M-0.39M-0.40M-0.41M
Other Working Capital ChangesOther WC Changes -1.01M0.19M-0.47M-0.53M0.26M-0.52M0.54M-0.61M-2.44M-0.72M-2.57M1.76M-1.97M-1.52M0.49M
Cash from OperationsCash from Ops. -16.63M-18.37M-13.19M-13.95M-13.98M-14.87M-20.15M-17.81M-28.33M-21.72M-27.22M-29.55M-20.08M-21.14M-17.60M
Investing Activities
Capital ExpendituresCapex 0.03M0.01M0.08M0.02M0.19M0.21M0.08M0.29M0.04M0.01M
Change in Property, Plant and EquipmentChange in PP&E -0.03M-0.01M-0.08M-0.02M-0.19M-0.21M-0.08M-0.29M-0.04M-0.01M
Change in IntangiblesChange Intangibless 0.08M0.01M0.01M-0.01M
Purchase of InvestmentsInvestments Purchased 140.02M
Sale and Maturity of InvestmentsInvestments Sold 15.60M16.30M35.30M38.33M27.50M26.24M
Cash from Investing ActivitiesCash from Investing -0.11M-0.05M-0.07M-0.19M-0.22M-0.08M-93.58M15.60M-39.17M35.01M-101.69M27.46M14.26M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment 0.04M0.11M0.11M0.10M0.11M0.11M0.11M0.07M0.11M0.12M0.16M0.12M0.08M0.17M0.12M0.14M
Non-Current Debt -0.04M-0.11M-0.11M-0.10M-0.11M-0.11M-0.11M-0.07M-0.11M-0.12M-0.16M-0.12M-0.08M-0.17M-0.12M-0.14M
Net Debt Issuances and RepaymentsNet Debt Issuance -0.04M-0.11M-0.11M-0.10M-0.11M-0.11M-0.11M-0.07M-0.11M-0.12M-0.16M-0.12M-0.08M-0.17M-0.12M-0.14M
Change in Capital Stock
Common Stock IssuedStock Issued 0.03M0.01M0.01M0.03M100.25M88.76M6.67M0.04M0.02M0.17M-0.17M0.31M80.02M2.60M25.18M
Net Shares Issued and RepurchasedNet Shares Issued 0.03M0.01M0.01M0.03M100.25M88.76M6.67M0.04M0.02M0.17M-0.17M0.31M80.02M2.60M25.18M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 0.00M
Net Equity Issued and RepurchasedNet Equity Issued 0.03M0.01M0.01M0.03M100.25M88.76M6.67M0.04M0.02M0.17M-0.17M0.31M80.02M2.60M25.18M
Other financing activitiesOther financing -0.08M-0.01M0.02M
Cash from Financing ActivitiesCash from Financing -0.08M-0.10M-0.09M3.91M100.07M88.65M0.29M-0.07M-0.10M0.01M72.96M0.05M143.77M2.45M24.40M
Additional items
Change in Cash -16.81M-18.47M-13.33M-10.09M86.02M73.59M-20.08M-17.96M-122.01M-6.11M6.57M5.52M22.00M8.77M21.07M
Ending Cash Balance 97.40M80.59M62.12M48.79M38.70M124.72M198.31M178.23M160.27M38.27M32.16M38.73M44.24M66.25M75.02M96.08M
Free Cash FlowFCF -16.65M-18.39M-13.27M-13.97M-13.98M-15.05M-20.37M-17.89M-28.33M-21.72M-27.22M-29.84M-20.08M-21.18M-17.60M
Net Cash FlowNCF -16.81M-18.47M-13.29M-10.09M86.02M73.59M-20.08M-17.96M-122.01M-6.11M6.57M5.52M22.00M8.77M21.07M

Lexeo Therapeutics Cash Flow Statement API

Pull Lexeo Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=LXEO&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY